ClinicalTrials.gg
RecruitingNCT05656794CONSORT-PCUpdated Mar 23, 2026

Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer

A Phase 2 interventional study of Radiotherapy in Prostate Metastases, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Neoplasm Metastasis by University Health Network, Toronto — 10 open to participants now, 15 under way, 2 of them phase 3. Neoplasm Metastasis · University Health Network, Toronto.

Planned enrollment
9th of 27
40 · median 25
Started
2023
with 1 other
Phase 2
13 of 36
1 open now
Primary completion
2031-08
later than 12 of 14 live
Registered
30th of 36
by date

Among the 36 studies in Neoplasm Metastasis by University Health Network, Toronto, this one is the 9th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2023, is one of 13 in phase 2, reaches primary completion later than 12 of the 14 other live ones, and was the 30th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

10 of the 36 studies in Neoplasm Metastasis by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Neoplasm Metastasis by University Health Network, Toronto, or all of them as a file.
02

Study summary

This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.

03

Conditions studied

  • Prostate Metastases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven prostate cancer
  • Presence of low-volume or high-volume (high volume defined as the presence of visceral metastases or ≥4 bone lesions with at least 1 lesion beyond the vertebral bodies and pelvis.)
  • Planned to or receiving systemic treatment ADT +/- ARAT as per physician discretion (Previous chemotherapy allowed if completed more than 6 weeks prior to randomization.)
  • Planned for EBRT
  • 0 or 1
  • Age 18 years or older

Exclusion criteria

Exclusion Criteria:

  • Prior radiotherapy to pelvis
  • Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
  • Any condition where radiotherapy is
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Arm 1 - Investigational

    Radiation treatment (36 Gy in 6 fractions) to be delivered every other day over 2 weeks (excluding weekends).

    Radiation: Radiotherapy

  • Other
    Arm 2 - Standard

    Radiation treatment (36 Gy in 6 fractions) to be delivered once a week over 6 weeks.

    Radiation: Radiotherapy

Interventions

  • RadiationRadiotherapy

    Standard of care radiotherapy administered as per institutional guidelines.

06

What researchers measure

Primary outcomes

  1. Rates of acute toxicity

    Compare rates of acute toxicity between participants in Arm 1 and Arm 2. Acute toxicity will be measured using CTCAE V5.0

    Time frame: 5 years

Secondary outcomes

  1. Rates of late toxicity.

    Compare rates of late toxicity between participants in Arm 1 and Arm 2. Late toxicity will be measured using CTCAE V5.0

    Time frame: 5 years

  2. Measure failure-free survival

    Compare failure-free survival, collected through medical records, for participants in Arm 1 and Arm 2

    Time frame: 5 years

  3. Quality of Life Outcomes

    EPIC-26 Questionnaire

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2031, 96 months after the start.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's planned 96 months is above that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2022
First posted
Dec 19, 2022
StartActual
Aug 9, 2023
Primary completionEst.
Aug 2031
CompletionEst.
Aug 2031
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05656794
Collaborators
TerSera Therapeutics LLC
Responsible party
Sponsor
First posted
Dec 19, 2022
Start date
Aug 9, 2023
Primary completion
Aug 2031 (estimated)
Completion
Aug 2031 (estimated)
Last update
Mar 23, 2026

Study contacts

Peter Chung, MD
Contact
peter.chung@rmp.uhn.ca
416-946-4501 ext. 2126

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion